GlassScriptPhysician profile
Amber Payne
NPI 1104830686
$5,074.52
in general payments reported to CMS, 2019-2025
33 companies · $1,179 in 2025
The $1,179 reported for 2025 was more than what 86% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,140 · 2022: $660 · 2023: $838 · 2024: $1,257 · 2025: $1,179.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,229 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,229.37 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $690.53 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $660.50 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $463.03 | 2021-2025 | Jardiance |
| Abbvie INC. | $409.27 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $322.84 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Takeda Pharmaceuticals U.S.A., INC. | $321.43 | 2021-2025 | Trintellix |
| Pfizer INC. | $250.72 | 2021-2025 | |
| Inspire Medical Systems, INC. | $244.52 | 2024 | Inspire |
| Astellas Pharma US INC | $205.81 | 2021-2025 | Veozah, Myrbetriq |
| Abbott Laboratories | $185.99 | 2022-2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $174.44 | 2021-2025 | |
| Dexcom, INC. | $142.83 | 2022-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $119.42 | 2021-2024 | Gardasil 9, Capvaxive, Gardasil |
| Lundbeck LLC | $97.13 | 2021-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $94.71 | 2022-2025 | Rexulti |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $90.71 | 2025 | Korlym |
| Exact Sciences Corporation | $83.20 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $82.01 | 2021-2024 | |
| Amgen INC. | $78.49 | 2021-2024 | Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $50.84 | 2021 | |
| Glaxosmithkline, LLC. | $47.95 | 2021-2023 | Arexvy |
| Xeris Pharmaceuticals, INC. | $39.43 | 2024-2025 | Gvoke Hypopen, Recorlev |
| Dynavax Technologies Corporation | $37.84 | 2023-2024 | Heplisav-B |
| Eisai INC. | $34.38 | 2021 | |
| Biogen, INC. | $25.84 | 2025 | Skyclarys |
| Alk-Abello, INC | $24.10 | 2025 | Neffy, Grastek, Ragwitek |
| Novartis Pharmaceuticals Corporation | $17.13 | 2022 | |
| Medline Industries LP | $15.11 | 2023 | |
| Upsher-Smith Laboratories LLC | $14.23 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.92 | 2021 | |
| Mylan Specialty L.P. | $12.58 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $11.91 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $11.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Payne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.